6-chloro-3,4-dihydro-3,3-dimethyl-2-quinoxalinone | 81016-66-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 6-chloro-3,4-dihydro-3,3-dimethyl-2-quinoxalinone
• 英文别名: 6-Chloro-3,3-dimethyl-1,2,3,4-tetrahydroquinoxal in-2-one；6-Chloro-3,3-dimethyl-1,2,3,4-tetrahydroquinoxalin-2-one；6-chloro-3,3-dimethyl-1,4-dihydroquinoxalin-2-one
• CAS: 81016-66-2
• 化学式: C₁₀H₁₁ClN₂O
• 分子量: 210.663
• InChiKey: MDIKUHNABMMQPX-UHFFFAOYSA-N

物化性质

• 熔点：
  175-176 °C
• 沸点：
  369.3±42.0 °C(Predicted)
• 密度：
  1.202±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-chloro-3,4-dihydro-3,3-dimethyl-2-quinoxalinone 在 potassium tert-butylate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 17.0h， 生成
  参考文献：
  名称：

  Piperazine Imidazo[1,5-a]quinoxaline Ureas as High-Affinity GABA_A Ligands of Dual Functionality

  摘要：

  A series of imidazo[1,5-alpha]quinoxaline piperazine ureas appended with a tert-butyl ester side chain at the 3-position was developed. Analogues within this series have high affinity for the gamma-aminobutyric acid A (GABA(A))/benzodiazepine receptor complex with efficacies ranging from inverse agonists to full agonists. Many analogues were found to be partial agonists as indicated by [S-35]TBPS and Cl- current ratios. Uniquely, a number of these analogues were found to have a bell-shaped dose-response profile in the alpha(1)beta(2)gamma(2) subtype as determined by whole cell patch-clamp technique, where in vitro efficacy was found to decrease with increasing drug concentration. Many of the compounds from this series were effective in antagonizing metrazole-induced seizures, consistent with anticonvulsant and possibly anxiolytic activity. Additionally, several analogues were also effective in lowering cGMP levels (to control values) after applied stress, also consistent with anxiolytic-like properties. The most effective compounds in these screens were also active in animal models of anxiety such as the Vogel and Geller assays. The use of the piperazine substituent allowed for excellent drug levels and a long duration of action in the central nervous system for many of the quinoxalines, as determined by ex vivo assay. Pharmacokinetic analysis of several compounds indicated excellent oral bioavailability and a reasonable half-life in rats. From this series emerged two partial agonists (55, 91) which had good activity in anxiolytic models, acceptable pharmacokinetics, and minimal benzodiazepine-type side effects.

  DOI：

  10.1021/jm9801307
• 作为产物：
  描述：

  N-(5-chloro-2-nitrophenyl)-2-methylalanine 在 titanium(III) chloride 、 sodium acetate 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 6-chloro-3,4-dihydro-3,3-dimethyl-2-quinoxalinone
  参考文献：
  名称：

  High-Affinity Partial Agonist Imidazo[1,5-a]quinoxaline Amides, Carbamates, and Ureas at the γ-Aminobutyric Acid A/Benzodiazepine Receptor Complex

  摘要：

  A series of imidazo[1,5-alpha]quinoxaline amides, carbamates, and ureas which have high affinity for the gamma-aminobutyric acid A/benzodiazepine receptor complex was developed. Compounds within this class have varying efficacies racing from antagonists to full agonists. However, most analogs were found to be partial agonists as indicated by [S-35]TBPS and Cl- current ratios. Many of these compounds were also effective in antagonizing metrazole-induced seizures in accordance with anticonvulsant and possible anxiolytic activity. Selected quinoxalines displayed limited benzodiazepine-type side effects such as ethanol potentiation and physical dependence in animal models. Dimethylamino urea 41 emerged as the most interesting analog, having a partial agonist profile in vitro while possessing useful activity in animal models of anxiety such as the Vogel and Geller assays. In accordance with its partial agonist profile, 41 was devoid of typical benzodiazepine side effects.

  DOI：

  10.1021/jm940765f

文献信息

• Practical synthesis of 3,3-substituted dihydroquinoxalin-2-ones from aryl 1,2-diamines using the Bargellini reaction
  作者：Thomas A. Alanine、Stephen Stokes、James S. Scott

  DOI：10.1016/j.tetlet.2016.08.057

  日期：2016.9

  The reaction of aromatic 1,2-diamines with trichloromethylcarbinols under mild, basic phase-transfer conditions provided expedient access to 3,3-disubsituted quinoxalin-2(1H)-ones in good to moderate yields. The use of unsymmetrical aryl diamines gave a regioisomeric mixture of products with the ratio shown to be dependent on the electronic nature of the aromatic substituents. 2,3-Diaminopyridines

  在温和的碱性相转移条件下，芳族1,2-二胺与三氯甲基甲醇的反应可方便地获得3,3-二取代的喹喔啉-2（1 H）-酮，收率良好。不对称芳基二胺的使用产生了产物的区域异构混合物，其比例显示出取决于芳族取代基的电子性质。也可以使用2，3-二氨基吡啶，其对二氢[3，2 - b ]吡啶并吡嗪-2-酮异构体表现出优异的选择性。
• Imidazo[1,5-A]quinoxalines
  申请人：The Upjohn Company

  公开号：US05541324A1

  公开（公告）日：1996-07-30

  An invention relating to Imidazo[1,5-a]quinoxalines (I) ##STR1## which do not contain an endocyclic carbonyl group and which are useful as anxiolytic and sedative/hypnotic agents.

  一种与咪唑并[1,5-a]喹啉(I)有关的发明，其不含内环羰基团，并且可用作抗焦虑和镇静/催眠剂。
• 4,5-cyclicimidazo[1,5-A]quinoxalines
  申请人：Pharmacia & Upjohn Company

  公开号：US05668282A1

  公开（公告）日：1997-09-16

  The invention discloses imidazo[1,5-a]quinoxalines (I) ##STR1## which do not contain an endocyclic carbonyl group that are useful as anxiolytic and sedative/hypnotic agents.

  本发明揭示了不含内环羰基的咪唑[1,5-a]喹啉(I) ##STR1## 作为抗焦虑和镇静/催眠剂使用。
• 5,6-cyclicimidazo [1,5-a] Quinoxalines
  申请人：The Upjohn Company

  公开号：US05574038A1

  公开（公告）日：1996-11-12

  The invention discloses imidazo[1,5-a]quinoxalines (I) ##STR1## which do not contain an endocyclic carbonyl group that are useful as anxiolytic and sedative/hypnotic agents.

  本发明揭示了不含内环羰基的咪唑并[1,5-a]喹啉(I) ##STR1## 作为抗焦虑和镇静/催眠剂。
• Hindered Amines¹. 3,3-Dialkyl-1,2,3,4-tetrahydro-2-quinoxalinones and<i>cis</i>- and<i>trans</i>-3,3-Dialkyldecahydro-2-quinoxalinones
  作者：John T. Lai

  DOI：10.1055/s-1982-29706

  日期：——